Intracranialgerminomasareraretumorsaffectingmostlypatientsatyoungage.Therefore,moleculardataonits etiopathogenesisarescarce.Wepresentaclinicalcaseofamalepatientof25 yearswithanintracranialgerminoma and a 16p11.2 microdeletion. His initial complaints were related to obesity, loss of facial hair and polydipsia. He also hadahistoryofsocial-interactiondifficultiesduringchildhood.Hisbloodtestswereconsistentwithhypogonadotropic hypogonadismandsecondaryadrenalinsufficiency,andhehadbeenpreviouslydiagnosedwithhypothyroidism.Healso presentedwithpolyuriaandpolydipsiaandthewaterdeprivationtestconfirmedthediagnosisofdiabetesinsipidus.His sellar magnetic resonance imaging (MRI) showed two lesions: one located in the pineal gland and other in the suprasellar region, both with characteristics suggestive of germinoma. Chromosomal microarray analysis was performed due to the associationofobesitywithsocialdisability,andtheresultidentifieda604 kb16p11.2microdeletion.Thesurgicalbiopsy confirmedthehistologicaldiagnosisofagerminoma.Pharmacologicaltreatmentwithtestosterone,hydrocortisone anddesmopressinwasstarted,andthepatientunderwentradiotherapy(40 Gydividedin25fractions).Threemonths afterradiotherapy,asignificantdecreaseinsuprasellarandpineallesionswithoutimprovementinpituitaryhormonal deficiencieswasobserved.Thepatientiscurrentlyunderfollow-up.Tothebestofourknowledge,wedescribethefirst germinoma in a patient with a 16p11.2 deletion syndrome, raising the question about the impact of this genetic alteration on tumorigenesis and highlighting the need of molecular analysis of germ cell tumors as only little is known about their genetic background.
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Learning points:
• • Centralnervoussystemgermcelltumors(CNSGTs)arerareintracranialtumorsthataffectmainlyyoungmale patients. They are typically located in the pineal and suprasellar regions and patients frequently present with symptoms of hypopituitarism.
• • The molecular pathology of CNSGTs is unknown, but it has been associated with gain of function of the KIT gene, isochromosome12pamplificationandalowDNAmethylation.
• • Germinoma is a radiosensitive tumor whose diagnosis depends on imaging, tumor marker detection, surgical biopsyandcerebrospinalfluidcytology.
• • 16p11.2 microdeletion syndrome is phenotypically characterized by developmental delay, intellectual disability and autism spectrum disorders.
• • Seminoma, cholesteatoma, desmoid tumor, leiomyoma and Wilms tumor have been described in a few patients with 16p11.2 deletion.
• 
Background
Intracranial germ cell tumors (IGCTs) are rare neoplasms with an overall incidence of 0.6 and 1.0 per million per year in the United States and in Europe, respectively, and have a peak incidence near the time of puberty (1). These tumors have a male-to-female ratio of 3-4:1 and about 50% are present in the pineal gland (1) . IGCTs are classified histologically in two main groups: pure germinoma and non-germinomatous germ cell tumors (1, 2) . Germinoma is the most common subtype, and it is present in about two-thirds of patients (1) . Their diagnosis and management are complex due to their heterogeneous clinical presentation, variable tumor location and different treatment approaches and outcomes. Furthermore, the scarcity of this neoplasms and, as so, their low availability for molecular analysis has hampered the understanding of the pathogenesis of IGCTs. Studies have demonstrated that KIT/RAS signaling pathway is frequently overactive in more than 50% of these tumors (1), the amplification of 12p is present in approximately 50% of CNSGTs (3) and, regarding epigenetic modifications, more than 60% of germinomas were clustered in a low methylation profile (3).
Case presentation
A 25-year-old man was referred to our endocrinology outpatient clinic because of grade III obesity. He complained of significant weight gain in the last 10 years and was medicated with 50 µg/day of levothyroxine for hypothyroidism without a defined etiology. He admitted a reduced libido without erectile dysfunction, polydipsia (>5 litter of water/day) and polyuria. His mother mentioned that he had social-interaction difficulties since he was a child. On physical examination, he presented a BMI of 46 kg/m 2 , abdominal perimeter of 132 cm, loss of facial hair and bilateral reduced testicular volume (right testicular volume of 12 mL and left testicular volume of 10 mL, as assessed by Prader orchidometer). He also presented macrocephaly, a broad forehead, a broad and prominent nasal bridge, anteverted nares and a small brachydactyly of the fourth and fifth fingers.
Investigation
The biochemical endocrine work-up showed the following results: follicle-stimulating hormone (FSH) <0.3 mIU/mL (<15), luteinising hormone (LH) <0.1 mIU/mL (<9), total testosterone 0.4 ng/mL (2.7-11), prolactin 16 ng/mL (<18), thyroid-stimulating hormone (TSH) 0.47 µIU/mL (0.4-4) and free thyroxine (FT4) 0.8 ng/dL (0.8-1.9), under 50 µg/day of levothyroxine. His growth hormone (GH) and insulin-like growth factor 1 (IGF-1) plasmatic levels were within the normal range ( The sellar and parasellar MRI showed two solid expansive lesions: one with 13 mm in the suprasellar region and another with 9 mm with a pineal location, isointense to the brain and with a homogeneous contrast enhancement on T1-weighted image, suggestive of a germinoma (Fig. 1) . Tumor markers α-fetoprotein and β-subunit of human chorionic gonadotropin (β-hCG) were not elevated in the serum and β-hCG in cerebrospinal fluid was slightly elevated in the initial work-up ( Table 1) . The patient performed a testicular ultrasound that revealed decreased testicular size (right testicular dimensions of 27 × 21 × 13 mm and left testicular dimensions of 22 × 14 × 13 mm) without further alterations. Computed tomography of chest, abdomen and pelvis was reported as normal. The mineral bone densitometry revealed a T-score of −1. (Fig. 2 ).
An open biopsy of the suprasellar lesion was performed via right pterional craniotomy and histological study revealed a germ cell tumor of germinoma type, with associated lymphocytic inflammatory infiltrate mainly composed of B lymphocytes (CD20+) and T lymphocytes (CD4+ and CD8+). The immunohistochemical analysis demonstrated positivity of the tumor cells for placental alkaline phosphatase (PLAP), CD117, octamer-binding transcription factor 4 (OCT 4) and sal-like protein 4 (SALL4), and it was cytokeratin CAM 5.2 and β-hCG negative.
Treatment
Treatment with testosterone in a dosage of 125 mg each 4 weeks, hydrocortisone 10 mg at wake time and 5 mg in the afternoon and desmopressin 0.06 mg/day was started. Levothyroxine dosage was titrated up to 175 µg/day according to patients' periodical biochemical analysis, to a target of normal FT4 level (0.8-1.9 ng/dL). His testosterone levels were within the normal range after 12 weeks of hormonal replacement (6.9 ng/mL, reference range: 2.7-11) and a significant improvement on his polyuria and polydipsia complaints was observed. After a multidisciplinary discussion, radiotherapy of the ventricular system and tumor locations was initiated in a total dose of 24 Gy in 15 fractions followed by a primary tumor boost of 16 Gy in ten fractions, without adverse reactions.
Outcome and follow-up
Radiotherapy was well tolerated. Three months after the completion of this treatment, the patient achieved a significant radiological improvement: his MRI revealed a substantial reduction of the suprasellar lesion, which currently involves only the pituitary stalk and hypothalamo-hypophyseal junctional area, and the pineal lesion was not observed (Fig. 3) .
At this time, the patient reported weakness and fatigue. Biochemical evaluation was performed, after withdrawing hydrocortisone for 24 h under supervision and revealed morning serum cortisol of 0.6 μg/dL (5-25), ACTH 9.5 pg/ mL (9-52), FSH <0.1 mIU/mL (<15), LH <0.1 mIU/mL (<9.0), total testosterone 1.7 ng/mL (2.7-11.0), TSH <0.004 µIU/mL, FT4 1.2 ng/dL (0.8-1.9), GH <0.1 µg/mL (<1), IGF-1 62 ng/mL (117-329). The patient reported improvement in polydipsia and polyuria complaints and, for this reason, he decided to suspend desmopressin therapy 2 weeks before biochemical tests. He presented a 24-h diuresis of approximately 4700 mL and a urinary density of 1.003 (1.010-1.030), urinary osmolality of 107 (300-900 mosmol/kg), plasmatic osmolality of 295 (260-302 mosmol/kg) and plasmatic sodium of 150 (136-146 mmol/L). Patients' hydrocortisone dosage was increased to 10 mg at wake time, 5 mg at lunch and 5 mg in the afternoon, and he was advised to restart desmopressin 0.06 mg per day. He remains under surveillance and regular follow-up appointments were scheduled.
Discussion
We present an unusual case of a primary intracranial germinoma in a patient with 16p11.2 microdeletion syndrome, an association not previously reported in the literature. Intracranial germinomas are rare tumors occurring mostly in children and young adults. Their first clinical manifestations may be related to hypopituitarism, and they are frequently diagnosed by clinical endocrinologists. The diagnosis is usually made by stereotactic or endoscopic biopsy in conjunction with blood and cerebrospinal fluid tumor markers, specially α-fetoprotein and β-hCG, which help in differential diagnosis (3). These tumors usually have an excellent response to radiotherapy, contrary to other ICGTs, which makes their histological diagnosis a fundamental step in the choice of patient's treatment and follow-up (4). Regarding associated endocrine manifestations, studies suggest that patients do not recover completely after radiotherapy; in fact, pituitary deficiencies may even increase in severity, and hormonal replacement treatment is usually necessary for their entire life (5). Owing to their low incidence and non-surgical treatment options, ICGTs remain one of the less explored brain tumors of young patients. However, the elucidation of these tumors' pathogenesis is essential to identify new biological markers useful for diagnosis and follow-up, as well as to unveil new therapeutic targets for refractory cases (6) . Therefore, recent studies have focused on the molecular pathology of CNSGTs. The most remarkable chromosome alteration is the amplification of 12p, present in more than half of CNSGTs (3); the gain-of-function in the KIT gene, a proto-oncogene, represents the main genetic change, and the KIT protein is overexpressed in approximately 60% of CNSGTs (3).
The human 16p11.2 microdeletion has a population prevalence of approximately 1/2000 (7) and is associated with variable clinical features that include learning difficulties/intellectual disability, social impairment, autism, delayed language, obesity/overweight and minor dysmorphic facial features (8) . A variety of rare clinical features have been associated with this deletion and tumors as seminoma, cholesteatoma, desmoid tumor, leiomyoma and Wilms tumor have been described in a few patients, suggesting either fortuitous associations or low penetrance through unmasking of recessive mutations (7, 9) . The scarcity of ICGTs and the lack of an in-depth characterization of their genotype make it difficult to understand the true mechanisms beyond these associations. To the best of our knowledge, there are currently no studies reporting an association between 16p11.2 deletion and germ cell tumors. Therefore, we may hypothesize that this deletion may be involved in promoting cell proliferation, contributing to tumorigenesis. In fact, some of the genes within the deleted area (Table 2 ) are associated with cell cycle proliferation and cellular replication, namely mitogenactivated protein kinase 3 (MAPK3) (10) .
The limited available data and the phenotypic heterogeneity of the syndrome are important pitfalls that need to be overcome to get a clear picture on this relationship. Future studies should evaluate the influence of additional genetic and environmental factors in shaping the phenotype of this syndrome. A comprehensive knowledge of the molecular mechanisms involved may have a relevant impact on patient's diagnosis, treatment and follow-up and may help in the management of endocrine insufficiencies, with the potential to reduce the undesirable effects of current therapeutic approaches.
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